Intellia

Intellia
Focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies.
Gene Editing
CRISPR Technology
Cell Engineering
Bioinformatics
Drug Development
Intelliaの求人
求人0件
現在募集中の求人はありません
製品・サービス
CR
CRISPR/Cas9 Gene Editing Platform
Gene Editing Technology
NT
NTLA-2001
Gene Editing Therapy
NT
NTLA-3001
Gene Editing Therapy
EX
Ex Vivo Cell Engineering
Cell Engineering Service
NT
NTLA-2002
Gene Editing Therapy
NE
Neurological Disease Programs
Gene Editing Therapy
PR
Primary Hyperoxaluria Program
Gene Editing Therapy
MO
Modular CRISPR Platform
Platform Technology
AS
ASGR1 Program
Gene Editing Therapy
IN
In Vivo Gene Editing Services
Gene Editing Service
LI
Lipid Nanoparticle Delivery System
Drug Delivery Technology

NTLA-5001
Cell Therapy
IM
Immunology Pipeline
Therapeutic Pipeline

NTLA-2003
Gene Editing Therapy

Asgard Platform
Platform Technology
LI
Lipid Nanoparticle Platform
Technology Platform
ON
Oncology Cell Therapies
Cell Therapy

Engineered Cell Medicines
Cell Therapy
CR
CRISPR Platform Technology
Technology Platform
類似企業

Merck
Multinational pharmaceutical company.
Rahway, New Jersey
10,001+名
Public
企業価値 $208B
848件の求人

Insulet
Multinational healthcare company.
Bedford, Massachusetts, United States
501-1,000名
Public
企業価値 $2.1B

Mammoth Biosciences
Biotechnology company.
San Francisco, California, United States
51-200名
Private
企業価値 $800M
2件の求人

Pfizer
Breakthroughs that change patients' lives.
New York City, New York
10,001+名
Public
企業価値 $280B
499件の求人

Bluebird Bio
Develops gene therapies for severe genetic disorders.
Somerville, Massachusetts
201-500名
Public
企業価値 $350M
最新情報
All
X
News
HN
YouTube
Intellia Files BLA After Lonvo-z Meets Phase 3 Endpoints - CRISPR Medicine News
CRISPR Medicine News
News
·
1ヶ月前
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
·
1ヶ月前
·
1
Cathie Wood Offloads Rocket Lab Stock (RKLB) Despite 3% Jump, Buys the Dip in Intellia (NTLA) - TipRanks.com
Bull signal if I ever saw one
·
1ヶ月前
·
89
·
34
Why Intellia Therapeutics (NTLA) Is Down 13.8% After Positive Phase 3 HAE Gene-Editing Results And FDA Filing - simplywall.st
simplywall.st
News
·
1ヶ月前
Intellia races in vivo CRISPR therapy to FDA after phase 3 data paint ‘compelling’ picture
·
1ヶ月前
·
28
もっと見る (残り15件)
閲覧数
0
応募クリック
0
Mock Apply
0
スクラップ
0
レビュー
2.7
2件のレビュー
ワークライフバランス
3.0
報酬
3.0
企業文化
2.0
キャリア
2.5
経営陣
1.5
25%
知人への推奨率
良い点
Potential for meaningful medical impact
Working on innovative treatments
Opportunity to help patients with rare diseases
改善点
Poor management decisions
Unfair layoff practices
Favoritism in promotions
給与レンジ
47件のデータ
Mid/L4
Mid/L4
1件のレポート
$214,500
年収総額
基本給
$165,000
ストック
-
$214,500
$214,500
面接レビュー
レビュー1件
難易度
3.0
/ 5
期間
2-5w
面接プロセス
1
Application Review
2
HR Screen
3
Hiring Manager Interview
4
Panel Interview
5
Offer
連絡先・所在地